These are a group of blood disorders where the bone marrow makes too many blood cells. This overproduction can lead to various problems, like enlarged spleen or liver, and sometimes blood clots or bleeding. The main cause is often a change in a specific protein called JAK2.
Every report comes from a Lived member, sent anonymously.
Have you tried Hydroxyurea for Myeloproliferative Disorders?
Myeloproliferative disorders, now usually called myeloproliferative neoplasms (MPNs), are a group of chronic blood cancers in which the bone marrow makes too many of one or more types of blood cell. The bone marrow is the spongy tissue inside bones where red blood cells, white blood cells and platelets are produced. In an MPN, that production keeps running when the body does not need it, and the extra cells cause most of the problems. The main types are named for the cells involved. Polycythemia vera makes too many red blood cells, which thickens the blood. Essential thrombocythemia makes too many platelets, the cells that help blood clot. In primary myelofibrosis, scar-like fibers build up in the marrow, so over time it makes fewer healthy cells and the spleen and liver try to take over. Chronic myeloid leukemia is also classed as an MPN, but it has its own distinct treatment and is usually managed as a separate disease. A few rarer types involve particular kinds of white blood cells. Many people have no symptoms at first, and the condition is often found on a routine blood test. Most MPNs develop slowly over years. Their seriousness comes mainly from a higher risk of blood clots and bleeding, and from the chance that the disease changes into a more advanced form.
MPNs start when a blood-forming stem cell in the bone marrow picks up a genetic change, called a driver mutation, that switches on cell growth. The most common changes are in genes named JAK2, CALR and MPL. Nearly everyone with polycythemia vera has a JAK2 change. These mutations are acquired during life and are found only in blood-forming cells, so in most people the condition is not inherited and cannot be passed to children. Researchers believe the mutations can arise decades before the disease is noticed. What triggers the mutation in the first place is usually unknown. Age is the clearest risk factor: polycythemia vera usually appears around age 60, and myelofibrosis is most often diagnosed between 50 and 80, though MPNs can occur at younger ages. Polycythemia vera is more common in men. In rare families, an inherited tendency raises the chance of developing an MPN, but even then people inherit a higher risk, not the disease itself.
Diagnosis usually begins with a complete blood count (CBC), which measures red blood cells, white blood cells, platelets and hemoglobin, the protein that carries oxygen. A count that stays high on repeated tests, without another explanation, raises the question of an MPN. A blood smear, where cells are examined under a microscope, can show abnormal shapes or immature cells. Genetic testing on a blood or bone marrow sample looks for the JAK2, CALR and MPL changes. Finding one strongly supports an MPN, although some people with myelofibrosis or essential thrombocythemia have none of them. When polycythemia vera is suspected, a blood test for erythropoietin, the hormone that tells the marrow to make red cells, is often checked; in polycythemia vera it tends to be low, because the marrow is overproducing on its own. A bone marrow biopsy, in which a needle removes a small sample of marrow and bone from the hip under local anesthetic, is often needed to confirm the type and to look for scarring. Telling essential thrombocythemia apart from early myelofibrosis matters, because the outlook and treatment differ. There is no standard staging system; instead, the specialist (a hematologist) estimates risk from the type, age, past clots, blood counts and genetic results.
Treatment depends on the type of MPN and on each person's risk, and its aims differ by type. For polycythemia vera and essential thrombocythemia, the main goal is to prevent clots and bleeding and to control symptoms. For myelofibrosis, it is to ease anemia, an enlarged spleen and symptoms such as fever, night sweats and weight loss. Current medicines control the disease rather than remove it, and most people continue treatment long term. Some people need no active treatment at first. Watchful waiting, meaning regular checkups and blood counts, is common for people with low-risk essential thrombocythemia and for myelofibrosis that causes no symptoms. For polycythemia vera, the usual starting point is phlebotomy, removing blood much like a blood donation, to bring the hematocrit (the share of the blood made up of red cells) below about 45%, along with low-dose aspirin to lower the chance of clots if it is safe for that person. Low-dose aspirin is also used for many people with essential thrombocythemia. People at higher risk of clots, usually those over 60 or who have already had a clot, are often offered a medicine that lowers blood counts. Hydroxyurea, an oral chemotherapy pill, is the most common first choice. Interferon treatments, including ropeginterferon alfa-2b (Besremi), an injection approved for adults with polycythemia vera or essential thrombocythemia, are another option; they need regular monitoring because they can cause or worsen depression and some autoimmune and other serious problems. Both hydroxyurea and interferon can harm a developing baby, so anyone who could become pregnant or is planning a pregnancy should talk with their hematologist before starting treatment or trying to conceive, since this affects which medicine is used and how a pregnancy is managed. Ruxolitinib (Jakafi) is a pill that blocks the overactive growth signal driven by JAK2 and related proteins, so it is called a JAK inhibitor. It is approved for intermediate- or high-risk myelofibrosis and for polycythemia vera when hydroxyurea has not worked or is not tolerated. It can shrink an enlarged spleen and relieve symptoms, but it can lower blood counts and raise the risk of infection, so blood tests are checked regularly. Other JAK inhibitors are options when ruxolitinib is not suitable. Anemia in myelofibrosis may be treated with transfusions or other medicines. For people with higher-risk myelofibrosis who are fit enough, a stem cell transplant from a donor is the preferred treatment and the main option aimed at changing the course of the disease rather than easing symptoms. It carries serious risks, including from the chemotherapy given beforehand, so the decision is made carefully with a transplant team. Clinical trials of newer targeted treatments are another option worth discussing with a hematologist.
Most MPNs are long-term conditions that people live with for many years. In studies of large groups, half of people with polycythemia vera lived about 15 years or longer after diagnosis and half of those with essential thrombocythemia about 18 years or longer, with considerably longer survival in people diagnosed at 40 or younger. Myelofibrosis is generally more serious, and its outlook varies widely with age, blood counts and genetic findings. These are group figures, and a hematologist can give a more individual picture. Daily life is often close to normal, especially early on. Some people deal with fatigue, itching (often after a warm bath or shower), headaches, a feeling of fullness under the left ribs from an enlarged spleen, or burning and redness in the hands and feet. Following the treatment plan, including aspirin and phlebotomy where prescribed, is the main way to lower the chance of clots. Follow-up is lifelong. Blood counts are checked regularly, sometimes every few weeks during phlebotomy or when starting a medicine, and less often once things are stable. Monitoring also watches for change over time: about 15% of people with polycythemia vera or essential thrombocythemia eventually develop myelofibrosis, and a smaller number develop acute leukemia, which is much harder to treat. Surgery, pregnancy and long periods of immobility can raise clot risk further and are worth planning with the care team.
See a doctor if a blood test shows high red cell, platelet or white cell counts that stay high, or if you notice persistent fullness or pain under the left ribs, itching after warm water, unexplained tiredness, drenching night sweats, weight loss, or easy bruising and bleeding. If you already have an MPN, contact your care team the same day for pain, swelling, warmth or redness in one leg, which can signal a clot in a deep vein. Also call the same day for a nosebleed or gum bleeding that will not stop, black or tarry stools or blood in your stool, which can mean bleeding in the stomach or bowel, or a fever while taking a medicine that lowers blood counts. Call 911 for sudden weakness or numbness on one side of the body, trouble speaking, sudden vision loss or a sudden severe headache, which can signal a stroke, or for sudden chest pain or shortness of breath, which can signal a heart attack or a clot in the lungs. Get emergency care right away for vomiting blood or material that looks like coffee grounds, or for heavy bleeding with dizziness or fainting.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share what living with Myeloproliferative Disorders is like, what's helped you, or ask the community a question.